Tim3/4 agonist therapeutics - LAPIX Therapeutics
Latest Information Update: 12 Jan 2024
At a glance
- Originator LAPIX Therapeutics
- Class Antiallergics; Food allergy immunotherapies
- Mechanism of Action HAVCR2 protein modulators; TIMD4 protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Coeliac disease; Peanut hypersensitivity
Most Recent Events
- 21 Dec 2023 Early research in Coeliac disease in USA (PO) (LAPIX Therapeutics pipeline, December 2023)
- 21 Dec 2023 Early research in Peanut hypersensitivity in USA (PO) (LAPIX Therapeutics pipeline, December 2023)